

EDITORIAL

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology



INTRODUCTION

Since the beginning of 2020, the coronavirus disease 2019 (COVID-19) pandemic has progressively affected millions of people worldwide and has brought many uncertainties for patients, health professionals, and policymakers. According to the World Health Organization (WHO), as of 3 June 2021, there were 171 222 477 confirmed cases of COVID-19, including 3 686 142 deaths.¹

Published evidence consistently shows that cancer patients are at a higher risk of death from COVID-19.²⁻⁴ In the first months of the pandemic, all levels of care (screening, diagnosis, treatment, and follow-up) were disrupted.⁵⁻⁷ Moreover, cancer centers started prioritizing care services, cancelling nonurgent appointments, adapting treatment protocols, and shifting to home-based remote care relying on telemedicine consultations.^{5,7} The deferral of screening programs and cancer-directed interventions generates concerns for an increase in the number of patients diagnosed with advanced disease stage and poor outcomes.⁶⁻¹²

In these unprecedented circumstances, health care institutions, researchers, and policymakers adapted quickly with variably coordinated responses worldwide. Along with vaccine development and research for COVID-19 therapies, international collaborative registries such as the ESMO-CoCARE¹³ or CCC19¹⁴ initiatives were set up in record time with the aim to gather evidence from patients with cancer infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, many societies such as the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) published recommendations to provide guidance for cancer institutions, oncologists, and patients.¹⁵⁻¹⁷ However, this crisis also highlighted the need to optimize the delivery of care and the use of resources in clinical research. In this paper, we aim to capitalize on the lessons learnt from the impact of the COVID-19 pandemic on clinical trials and use them as a catalyst to launch a discussion over a framework of broader adaptations needed in the design and implementation of oncology clinical trials.

THE EARLY IMPACT OF THE COVID-19 PANDEMIC ON CLINICAL TRIAL PERFORMANCE

Even before the COVID-19 pandemic important barriers impacted on the conduct of clinical trials.¹⁸⁻²⁰ Different

research groups have been proposing a number of solutions in order to remedy the complex, and at times dysfunctional reality of clinical cancer research.¹⁹⁻²² To add to this background, clinical research activities were seriously impaired at the beginning of the SARS-CoV-2 pandemic, resulting in many sites struggling to maintain their trial activity and to start new studies.^{18,23-25} Recruitment of new patients and follow-up visits were reduced with the advent of lockdown measures in most places,^{26,27} while the pandemic and quarantine policies significantly affected research staff availability and performance. In a survey conducted by the ESMO Resilience Task Force in oncology professionals ($n = 1520$), 67% of responders reported a change in professional duties since COVID-19, 66% were not able to perform their job compared with the pre-COVID-19 period, and 38% experienced burnout symptoms.²⁸

As a consequence, the launch of new clinical trials, screening, and enrollment of new patients, clinical visits, updates of case report forms were affected.^{23,25,26,29} The pandemic also hindered patient empowerment (decision-making process) due to the distancing between investigators, caregivers, patients, and families. In fact, several background problems for clinical trial research became even more difficult to manage during the COVID-19 pandemic (Table 1).

The need for adjustments in clinical trial procedures prompted the European Medicines Agency (EMA) and American Food and Drug Administration (FDA) to publish guidance during the COVID-19 pandemic.^{29,30} At the same time, trial sponsors adapted protocols with a series of amendments, including the need to 'reconsent for trial enrollment during COVID-19'. Sponsors, investigators, and patients improvised with adaptation strategies while experts and scientific societies highlighted the need and opportunity to rethink how clinical trials are run.^{18,31-34} In Table 2 we recapitulate the educative lessons to be considered for the future of clinical research post-COVID-19 (Table 2).

BEYOND THE PANDEMIC: OPPORTUNITIES TO OPTIMIZE CLINICAL TRIAL IMPLEMENTATION

Reduce administrative load and optimize performance of clinical trials

In a recent survey by the ESMO Clinical Research Observatory (ECRO), clinical investigators ($n = 940$) strongly agreed on the excessive burden of administrative tasks that reflect negatively on the quality of clinical research.¹⁹ While adherence to international guidelines such as the Helsinki

Table 1. Obstacles in clinical research and their changes during the pandemic

Obstacles in clinical trial research before the SARS-CoV-2 pandemic	Deterioration during the SARS-CoV-2 pandemic
Excessive burden of administrative tasks Organizational, resource, and staff limitations to accommodate a growing number of novel-design clinical trials	More difficult to accommodate with restrictions in clinical and research activities Pandemic and quarantine policies significantly affected research staff availability and their burnout levels; significant reduction in clinical trial performance; inability to rapidly adapt to new research and clinical conditions
Excessive time in research meetings (local visits, audits, and data monitoring events)	Extremely difficult to accommodate with lockdown policies and reduced staff available
Length and complexity of informed consent	Patient empowerment reduced due to the distancing between investigators, patients, and caregivers; more reconsents needed
Patient difficulties to access research centers (living far, elderly, comorbidities, economic conditions)	Aggravated following lockdown measures and quarantine policies
Disproportionate/unnecessary number of time-demanding clinical trial appointments for patients	More difficult to maintain following lockdown measures and changes in hospital-care and research pathways
Restrictive eligibility criteria and under-representation of real-world population	Increased difficulty to keep enrollment goals with many patients reducing their hospital visits; low representativeness of patients at a higher risk of death from COVID-19 (e.g. elderly; patients with cancer or heart dysfunction) in vaccine pivotal trials.
Weak correlation between some surrogate endpoints and clinical meaningful outcomes	Unprecedented short landmarks in time for (COVID-19) vaccines efficacy considering the global urgency.
Significant dropout rates from clinical trials due to excessive administrative load, visits, or uncertainties with treatment efficacy and toxicity	Patients refraining from visiting cancer centers for treatments or follow-ups

COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Table 2. Pathways for optimizing oncology clinical trial implementation based on the coronavirus disease 2019 (COVID-19) pandemic experience as a catalyst

Pathways
Reduce administrative load, optimize performance of clinical trials <ul style="list-style-type: none"> • Reduce redundant documentation or procedures in strict compliance with good research practices • Revisit burdensome internal procedures of research sponsors • Reduce on-site and increase remote visits for research staff meetings, audits, and monitoring • Increase the use of validated artificial intelligence tools and text-mining technologies for data collection and monitoring • Develop organizational flexibility for novel research methodologies and technologies • Optimize research cooperation with national and international networks expanding clinical trial access to more centers and patients • Develop shared databases of resources and operational information related to investigators and logistics of trial implementation
Improve informed consent <ul style="list-style-type: none"> • Simplify informed consent (IC) and reconsent documents using readability methodologies • Promote use of remote electronic consent (eConsent), by either videoconference (oral) or procedures for e-signatures. Facilitate face-to-face meetings when easy to schedule or requested by patients • Develop specific eConsent guidelines to ensure patient empowerment • Engage patient representatives in the development of IC and eConsent documents • Increase patient literacy in clinical trial research, improving sources of e-information and web-based networking
Promote telemedicine and decentralize point of care <ul style="list-style-type: none"> • Expand use of telemedicine in oncology clinical trials • Provide research, training, and validate guidelines for telemedicine and remote procedures in clinical trials • Develop and use validated electronic patient reported outcomes and tools (quality of life scales; wearable devices; phone apps; online reports) with continuous data collection from patients, particularly in the adjuvant and curative trial settings • Involve regional centers close to patient residency as co-research institutions, allocating proper training and incentives • Allow examinations (clinical; laboratory; radiology) to be performed close to patient home with easy assessment by the main research institution • Deliver oral medicines to patient homes, with accountability, monitoring, compliance and follow-up procedures in place
Optimize clinical trial impact: trial population, endpoints, and validation <ul style="list-style-type: none"> • Use broader inclusion criteria in trials in select clinical circumstances, simulating real-world settings • Further develop novel trial designs, based on molecular enrichment, master protocols, and pragmatic control arms • Promote generation of real-world evidence from well-designed, high-quality complementary RWD studies • When surrogate endpoints are used in trials in areas of unmet need, validate any benefit from new drugs with the impact on clinically meaningful patient-centered endpoints in trials supplemented by RWD, preferably on overall survival and/or quality of life • Build consensus on significant methodology and quality requirements of RWD, along with development and validation of artificial intelligence tools linked to clinical evaluation of therapeutics and biomarkers

RWD, real-world data.

Declaration and good clinical practice regulations are *sine qua non*, their overinterpretation may undermine the efficiency in all clinical research processes. For instance, the General Data Protection Regulation 2016/679 (GDPR) of the European Union (EU), which came into force on 25 May 2018, raised concerns in the oncology community, due to the misinterpretation of the measures required by various clinical research stakeholders.²² Pharmaceutical industry

sponsors and contract research organizations commonly demand more rigid, burdensome administrative and recording procedures than those stipulated in international recommendations, with many of those extra tasks being extremely time and resource demanding. These factors decrease investigator motivation, hinder drug development, and patient's access to innovative treatments.^{19,21,35} This background problem became more complex to manage as

the pandemic started affecting health institutions, forcing research sponsors to revisit their internal procedures to facilitate implementation of clinical trials.

Well-conducted studies require resources, trained investigators, and dedicated teams. Lack of preparedness and mechanisms for flexible adaptation of these elements affected several research centers and contributed to the significant reduction in clinical trial activity.^{25,36} Organizations should develop a clear resilience plan to be implemented during challenging conditions (such as the pandemic), bringing together investigators, administrators, and patients for its development in a base-to-apex approach. Digital technologies and remote data collection/review approaches are integrative in such contingency plans.

Data monitoring events, local meetings, and audits are very demanding activities for sponsors and researchers¹⁹⁻²¹ and although necessary, they can be trimmed and be performed remotely, without compromising the integrity and quality of clinical research. This was successfully tested during the pandemic and could be continued in the future.³⁶⁻³⁹ Remote meetings, data verification, and monitoring (phone calls, video visits, emails) of data collected from each clinical trial site may be permitted in appropriately defined settings, after validated standard operating procedures are set in place. In addition, artificial intelligence tools and text-mining technologies for data collection, review, and monitoring, when properly validated, could be used to reduce the burden of work needed by a human hospital operator.⁴⁰⁻⁴²

Cancer clinical trials, especially early phase, are often run in centers in a ‘cocoon’ environment limited to the center. A functional web-based portal with a trial database and trial-specific contact points could promote awareness, diffuse information, and coordinate patient screening and accrual procedures across a vast network of centers. Moreover, although clinical trials are similar in their implementation conditions, commonly each local investigator team and each trial sponsor need to develop the administrative resource package from zero, resulting in loss of time and resources. Centralized, shared, updatable databases collecting all relevant data from trained investigators and sites (good clinical practice training records, financial disclosures, feasibility conditions, standardized Curriculum Vitae) can lead to more efficient, fast implementation of clinical trials. Such a strategy could be managed by regulators overseeing clinical research.

Improve informed consent

The informed consent (IC) is a cornerstone trial feature empowering patients and relatives with the most relevant information for their own decisions. With current practices it is often too complex, long, having excessive medical jargon, and time demanding for both patients and investigators.^{43,44} Besides, IC amendments are frequently required, and both patients and researchers need to go through a time-consuming process of reconsent. As the

pandemic surged worldwide, sponsors rapidly adapted their trials with amendments, resulting in more in-person visits for reconsents.

Over time, remote consents, which were not common before the pandemic, became progressively permitted either by videoconference (oral consent) or via electronic records and signatures. With modern technology and electronic security mechanisms in place, a remote consent (or reconsent) could be maintained after the pandemic, particularly for patients having difficulties to access the research center. However, provisions for face-to-face meetings and authorizations should be made possible, specifically if requested by the patient. The trend for more remote consents raises the need to develop specific eConsent guidelines and validation studies with close monitoring to ensure patient empowerment, efficiency, and data security.⁴⁵ An implementation process is needed to provide information on how to determine whether eConsent is a feasible approach, which multimedia components are a reasonably good fit for a specific study, and the external and internal data security/audit processes to consider when implementing.

In order to improve patient and relatives’ literacy in clinical research, dedicated sources of information should be developed. Web-based networks and compassionate communities can foster dialogue between patients and promote the exchange of information as well as literacy, participation, and compliance with clinical trials.⁴⁶⁻⁴⁸ Finally, new opportunities to improve and simplify ICs, such as applying readability methodologies,⁴⁹ shortening documents, and engaging patient’s advocates in IC development, will optimize patient empowerment.

Promote telemedicine and decentralize point of care

Different studies have reported significant dropout rates of cancer patients in clinical trials.⁵⁰⁻⁵² The extensive paperwork, number of visits, examinations might demotivate many patients and investigators from complying with intensive research protocols. These obstacles increased during the pandemic⁵³ with many patients self-isolating and dropping out from trials.^{26,27}

The average number of hospital visits for patients enrolled in clinical trials can be time consuming as the number of activities, such as toxicity assessment, physical examination, vital sign measurements, patient-reported outcome monitoring, blood tests, treatment administration contribute to long hours in the cancer center. Some of these tasks could be reduced, or assessed at home or in a nearest institution. Local health centers could be engaged in trials for clinical assessment or diagnostic examinations, where research teams should receive proper training, incentives, and be considered co-investigators, under the supervision of the main research team. These measures can bring several advantages: (i) patient comfort, (ii) access to research and financial incentives to local/regional centers, (iii) increase of recruitment of patients, and (iv) decrease of the workload pressure at the main institution center.

The EMA guidance for clinical trials during the pandemic accepted, exceptionally, laboratory examinations, imaging, or other diagnostic tests to be performed locally, outside the research center.²⁹ There are good reasons to keep this practice beyond pandemic times, including the lack of evidence supporting the superiority of central over local testing, at least for routine procedures. Nowadays, many diagnostic examinations can be performed under the same conditions in different institutions with proper certifications without undermining the quality of data. This patient-friendly policy may reduce disparities in access to clinical trials for patients living remotely.

For all these clinical and laboratory pathways, there must be an agreement between patients, research centers, and the sponsor, with scientific and financial incentives provided for local and regional centers by the latter. For laboratory examinations, it should be formally certified that the same methodologies and units are used, and data are easily interoperable, accessed, or sent to the main research center. Imaging modalities may also be decentralized, provided a standardized protocol is used for image acquisition, all examinations are digitized, stored securely, anonymized, and easily accessed by the main research center. Only essential study procedures, such as biomarker assessments or tumor biopsies, should be validated centrally for good scientific reasons.⁵⁴ In addition, in many countries and hospitals the delivery of cancer medication to patient's home expanded to more patients, clinical conditions, and drugs as a response to the pandemic. While not yet generalized in clinical trials, this could be considered in future for some oral treatments, after setting up proper protocols for drug delivery, accountability, and compliance monitoring.

Current clinical trial protocols are strict with face-to-face visits and do not consider remote appointments, despite provisional permission of telemedicine use during the pandemic. Reducing the number of appointments and converting some physical visits into telephone or video consultations (e.g. for safety reporting; clinical assessment) was a positive experience during the COVID-19 era,^{18,36,39,55} with high satisfaction rates reported from both clinical trial participants and investigators.^{56,57} Telemedicine could be contemplated in future clinical trial protocols, to ensure that only strictly necessary visits are performed at sites. However, specific guidelines and procedures should be very well defined in the protocol⁵⁸ and patients with lower technological skills should not be excluded or discriminated. Monitoring toxicity could be performed from distance only in low-grade cases, while upon suspicion of a significant adverse event or disease progression, the patient should have a face-to-face appointment as soon as possible in the primary or collaborating trial hospital. It must be noted that telemedicine requires dedicated time and conditions for all staff, proper technology infrastructure, training, and research into the adequate patient–doctor relationship adjustments. Moreover, it should be considered a regular clinical activity from all perspectives.

Novel electronic patient reported outcome strategies could be used to collect patient-level reliable data, while

reducing the number of physical appointments. These may include quality of life scales and use of wearable devices, phone apps, or online reports.^{59,60} The use of these remote monitoring tools can enable symptom management to be performed either remotely or locally at the patient's home. However, more research is needed before all these tools are properly validated to be considered in clinical trials, and this avenue should be pursued.⁶¹ To date, evidence of benefits of digital symptom monitoring has been largely focused on patients receiving treatment for metastatic cancer. There has been scant evaluation of impact on patients with curable disease receiving time-delimited adjuvant therapy who have minimal disease burden and symptoms.

Optimize clinical trial impact: trial population, endpoints, and validation

The scientific community has been identifying several challenges and opportunities to improve cancer clinical research.^{20,62–64} Before the pandemic, the restrictive eligibility criteria and under-representation of real-world population were already considered potential deficits in clinical trials.^{51,65} Elderly patients and those with severe comorbidities, abnormal laboratory profiles, or moderate performance status are commonly excluded from pivotal research, although they represent a significant proportion of the real-world cancer population.^{65–69}

Another important challenge for cancer research has been the definition of endpoints capturing relevant outcomes in each research setting as timely as possible, in order to provide the patient with rapid access to innovative therapeutics. Ideally, surrogate endpoints with strong correlation with clinically meaningful outcomes should serve this purpose, but few comply to this definition.^{70–72} As an example, after granting accelerated approval for several immune checkpoint inhibitors, the FDA announced that four indications were voluntarily withdrawn, and six others were under review, as reported results from confirmatory trials have not verified clinical benefit.⁷³ Consequently, surrogate endpoints, as important as they are to rapidly bring innovative treatments to patients with cancer, need to be validated in each context for their correlation with clinically meaningful outcomes, such as improvement of overall survival and/or quality of life, in the setting of clinical trials. Real-world data may be extremely important to validate such correlations in contexts in which trials are unethical (unmet need, no effective therapy) or not feasible (rare tumors).

In an analogous experience, the pandemic emergency led to the launch of several clinical research projects, vaccines were developed and approved in record time, and many real-world evidence studies were published. Shorter-term endpoints were used in COVID-19 trials, resulting in marketing authorization of several effective vaccines. However, relevant endpoints such as the long-term vaccine protection, interruption of virus transmission, and rare events were not considered, while some population groups (cancer, immunosuppression, adolescents) were not included, resulting in knowledge gaps.⁷⁴ To partly remedy this, close

monitoring with trials and real-world studies further confirmed vaccine effectiveness^{75,76} while safety signs were captured in time by pharmacovigilance systems.^{77,78} Nevertheless, there were also contradictory evidence from different real-world studies assessing some treatments against COVID-19, such as with chloroquine or remdesivir, due to variations in local management, data quality, and granularity.

The SARS-CoV-2 vaccine trial experience, and overall the challenges encountered in clinical trial activities due to the stress imposed by a viral pandemic, should become the catalyst for initiating a multistakeholder discussion on broader reforms in the design, organization, and implementation of clinical research in oncology. Inefficiencies highlighted by the pandemic can become opportunities to elicit carefully designed adaptations aiming to improve (i) representativeness of trial populations, (ii) balanced use of accelerated drug approvals based on surrogate endpoints, and (iii) validation of benefits from new drugs captured by surrogate endpoints in clinically relevant outcomes in trials and real-world data.^{79,80} Both before and certainly after the pandemic, we advocate for trials with relevant, patient-centered, and clinically meaningful endpoints in representative populations as similar as possible to real-world settings, while acknowledging the need for fast-track patient access to promising novel therapeutics. When proof of remarkable benefit is provided by a novel treatment in an area of unmet need in the setting of a clinical trial using surrogate endpoints, fast conditional approval can be justified, coupled to future validation in confirmatory studies (clinical trials supplemented with real-world data) assessing mature, clinically meaningful, 'hard' endpoints. In this setting, the role of real-world data as a synergistic and complementary research methodology to traditional randomized trials should be further assessed after building consensus on significant methodology and quality requirements.⁶³

The pandemic impact sorely stressed the need to study optimal paths for delivering these goals. Mechanisms such as the PRIME scheme launched by the EMA to enhance support for the development of medicines that target an unmet medical need could be expanded, with periodic reassessment.⁸¹ The development of artificial intelligence tools offers promise for the empowerment of real-world data in the assessment of therapeutics and biomarkers; however, they should be rigorously validated before general use.

Conclusion

The COVID-19 pandemic affected millions of people globally, and its effects on society, patients, health institutions, and governments may persist. Clinical trials are our best tool to improve cancer treatment for patients through testing the clinical value of a new treatment or intervention; however, they were particularly affected by the COVID pandemic, despite frantic adjustments. Still, the challenges imposed by the pandemic on daily running of clinical trials in oncology highlighted pre-existing inefficiencies. The

pandemic and its impact should be revisited as an opportunity and catalyst to ignite a discussion among all stakeholders on pragmatic reforms that will transcend through and expand beyond pandemic lessons, ultimately aiming to improve cancer clinical research in all contexts. The clinical trial administrative load could be significantly reduced, without affecting the quality of research and ethics principles. Cancer centers should adapt their structure faster to molecular oncology and novel trial designs. Importantly, the number of physical visits to research institutions could be reduced with telemedicine and routine examinations should be performed in local institutions (co-research centers), maintaining adherence to good clinical and research practices. Clinical trials should adopt broader inclusion criteria and better outcome definitions and be more focused on real-world population needs, while fast-track drug approvals based on surrogate endpoints should be linked to strict validation requirements. The COVID-19 pandemic is a dramatic and negative experience, however lessons learnt could be further developed in order to facilitate equitable access to clinical trials of real-world populations in a pragmatic, simplified, and methodologically robust modus operandi for the benefit of all our patients.

L. Castelo-Branco¹, A. Awada², G. Pentheroudakis^{1*}, J. L. Perez-Gracia³, J. Mateo⁴, G. Curigliano⁵, S. Banerjee⁶, R. Giuliani⁷, F. Lordick⁸, A. Cervantes⁹, J. Tabernero¹⁰ & S. Peters¹¹

¹*Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland;*

²*Head of the Oncology Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, Belgium;*

³*Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain;*

⁴*Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona;*

⁵*Istituto Europeo di Oncologia, IRCCS and University of Milano, Milano, Italy;*

⁶*The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London;*

⁷*The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK;*

⁸*Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Leipzig, Germany;*

⁹*Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Valencia;*

¹⁰*Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain;*

¹¹*Oncology Department — CHUV, Lausanne University, Lausanne, Switzerland*

(*E-mail: george.pentheroudakis@esmo.org).

Available online 24 July 2021

<https://doi.org/10.1016/j.esmoop.2021.100237>

ACKNOWLEDGEMENTS

The authors acknowledge Mrs Klizia Marinoni for the editorial assistance provided.

FUNDING

None declared.

DISCLOSURE

AA reports fees for advisory role, research grants to his institute, and speaker fees from Roche, Lilly, Amgen, Eisai, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck, and Daiichi. GP reports grants from Amgen and Lilly; grants, personal fees, and nonfinancial support from Merck; grants and nonfinancial support from AstraZeneca; grants and personal fees from Roche; grants and personal fees from Bristol Myers Squibb, MSD, and Novartis, outside the submitted work. JLP-G reports research grants and support from Roche, BMS, MSD, and Seattle Genetics; reports serving/served on the speakers bureau and advisory boards for Roche, BMS, Ipsen, MSD, and Seattle Genetics; and reports travel support from Roche, MSD, and BMS. JM has served on advisory boards for Amgen, AstraZeneca, Clovis Oncology, Janssen, Merck/MSD, Pfizer Oncology, and Roche; has participated in speakers bureau funded by AstraZeneca, Guardant Health, Merck/MSD, and Pfizer Oncology; has received research funding to the institution from AstraZeneca and Pfizer Oncology (not related to this work). GC reports personal fees from Roche, Pfizer, Novartis, Lilly, Foundation Medicine, BMS, Samsung, AstraZeneca, Daiichi Sankyo, Boehringer, GSK, Seagen; nonfinancial support from Roche and Pfizer; grants from Merck; and other from Ellipsis, outside the submitted work. SB reports advisory role for Amgen, AstraZeneca, Epsilogen, Genmab, GSK, Immunogen, Mersana, MSD, Merck Serono, OncXerna, Pfizer, and Roche. She reports lectures and continuing medical education: Amgen, Pfizer, AstraZeneca, Tesaro, GSK, Clovis, Takeda, Medscape, Research to Practice, PeerView; reports research support (paid to institution) for PI role from Global lead Verastem, European Organisation for Research and Treatment of Cancer (EORTC), AstraZeneca, Lady Garden Foundation Charity; and national principal investigator for Immunogen, Genmab, Seagen, Tesaro, GSK, Wellbeing of Women Charity, AstraZeneca, and Lady Garden Foundation Charity. RG reports being a core member of the European Medicines Agency Scientific Advisory Group Oncology, an expert evaluator for the EU Commission in 2020 on the topic 'Global Alliance for Chronic Diseases (GACD) 2 - Prevention and/or early diagnosis of cancer'; provides consultation/lectures (no remuneration) for Novartis, Mylan, Roche, Lilly, Apogen and Pfizer; and institutional financial support (clinical trials, Italy) from MSD and Novartis. FL reports honoraria for advisory board from Amgen, Astellas, Bayer, BeiGene, BMS, Eli Lilly, MSD, Roche, and Zymeworks; reports honoraria as invited speaker from AstraZeneca, BMS, Eli Lilly, Medscape, MedUpdate, Merck Serono, MSD, Roche, Promedica, Servier, Servier, streamedup!, and Imedex;

reports honoraria for expert testimony from BioNTech and Elsevier; reports honoraria for writing engagement from iOMEDICO, Springer-Nature, and Deutscher Ärzteverlag; and reports research grant from BMS. AC reports honoraria as invited speaker from Merck Serono, Amgen, Roche (invited speaker, institutional); reports honoraria for advisory board from Amgen and BeiGene; serves as an Associate Editor for *Annals of Oncology* and as an Editor for *Cancer Treatment Reviews*. He reports research grant as principal investigator (paid to institution) from AbbVie, Actuate Therapeutic, Alkermes Inc, Amgen, Astellas Pharma, BeiGene, Bioncotech Therapeutics, Boehringer Ingelheim, Debiopharm International, European Organisation for Research and Treatment of Cancer (EORTC), F. Hoffmann-La Roche, FibroGen, Genmab, Janssen Research & Development, MedImmune, Menarini Ricerche, Novartis, Puma Biotechnology, Symphogen, Tahio, Transgene, WNT Research, and Adaptimmune. JT reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech, Inc, HalioDx SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, NeoPhore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics, and TheraMyx; reports educational collaboration from Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, and Physicians Education Resource (PER). SP reports consultation/advisory role for AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Biocartis, Bio Invent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann-La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, Pharma Mar, Phosphatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody; reports talk in a company's organized public event for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, e-cancer, Eli Lilly, F. Hoffmann-La Roche/Genentech, Illumina, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, RTP, Sanofi, and Takeda; reports receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche/Genentech, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, Pfizer, and Phosphatin Therapeutics. LC-B has declared no conflicts of interest.

REFERENCES

1. WHO. Coronavirus disease (COVID-19)—World Health Organization. Available at <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed August 2, 2021.
2. Carreira H, Strongman H, Peppas M, et al. Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: a matched cohort study using linked English electronic

- health records data. *EClinicalMedicine*. 2020;29. <https://doi.org/10.1016/j.eclinm.2020.100656>.
3. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020;395(10241):1907-1918.
 4. Rüttrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. *Ann Hematol*. 2020;100(2):1-11.
 5. Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. *JCO Clin Cancer Inform*. 2020;4(4):1059-1071.
 6. Morris EJA, Goldacre R, Spata E, et al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. *Lancet Gastroenterol Hepatol*. 2021;6(3):199-208.
 7. Schrag D, Hershman DL, Basch E. Oncology practice during the COVID-19 pandemic. *J Am Med Assoc*. 2020;323:2005-2006.
 8. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh Q-D. Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. *JAMA Oncol*. 2021;7:458-460.
 9. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol*. 2020;21(8):1023-1034.
 10. Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. *BMJ*. 2020;371:m4087.
 11. Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. *Nat Cancer*. 2020;1(6):565-567.
 12. Jerusalem G, Onesti C, Generali D, et al. Expected medium and long term impact of the COVID-19 outbreak in oncology. *Ann Oncol*. 2020;31:S1205-S1206.
 13. ESMO. ESMO-CoCARE Registry. Available at <https://www.esmo.org/covid-19-and-cancer/collaborating-on-registries-studies-and-surveys/esmo-cocare-registry>. Accessed August 2, 2021.
 14. CCC19. The COVID-19 and Cancer Consortium. CCC19. Available at <https://ccc19.org/>. Accessed August 2, 2021.
 15. ESMO. COVID-19 and Cancer. Available at <https://www.esmo.org/covid-19-and-cancer>. Accessed August 2, 2021.
 16. Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol*. 2020;31(10):1320-1335.
 17. ASCO Coronavirus Resources. ASCO. 2020. Available at <https://www.asco.org/asco-coronavirus-information>. Accessed August 2, 2021.
 18. Doherty GJ, Goksu M, de Paula BHR. Rethinking cancer clinical trials for COVID-19 and beyond. *Nat Cancer*. 2020;1(6):568-572.
 19. Perez-Gracia JL, Awada A, Calvo E, et al. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. *ESMO Open*. 2020;5(3):e000662.
 20. Rule S, LeGouill S. Bureaucracy is strangling clinical research. *BMJ*. 2019;364:l1097.
 21. Gribben J, Macintyre E, Sonneveld P, et al. Reducing bureaucracy in clinical research: a call for action. *HemaSphere*. 2020;4(2):e352.
 22. Casali PG, Vyas M. Data protection and research in the European Union: a major step forward, with a step back. *Ann Oncol*. 2021;32(1):15-19.
 23. Tuttle KR. Impact of the COVID-19 pandemic on clinical research. *Nat Rev Nephrol*. 2020;16(10):562-564.
 24. Burki TK. Cuts in cancer research funding due to COVID-19. *Lancet Oncol*. 2021;22(1):e6.
 25. Lamont EB, Diamond SS, Katriel RG, et al. Trends in oncology clinical trials launched before and during the COVID-19 pandemic. *JAMA Netw Open*. 2021;4(1):e2036353.
 26. Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. *JAMA Netw Open*. 2020;3(6):e2010651.
 27. Fleury ME, Farner AM, Unger JM. Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials. *JAMA Oncol*. 2021;7(1):131-132.
 28. Banerjee S, Lim KHJ, Murali K, et al. The impact of COVID-19 on oncology professionals: results of the ESMO resilience task force survey collaboration. *ESMO Open*. 2021;6(2):100058.
 29. European Medicines Agency (EMA). Guidance on the Management of Clinical Trials During the Covid-19 (Coronavirus) Pandemic. Report No.: Version 3. Amsterdam, The Netherlands: EMA. Available at <https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-clinical-practice#guidance-on-clinical-trial-management-during-the-covid-19-pandemic-section>. Accessed August 2, 2021.
 30. US Food and Drug Administration (FDA). FDA Guidance on Conduct of Clinical Trials of Medical Products during the COVID-19 Public Health Emergency. Silver Spring, MD: FDA; 2021. Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency>. Accessed August 2, 2021.
 31. Marcum M, Kurtzweil N, Vollmer C, et al. COVID-19 pandemic and impact on cancer clinical trials: an academic medical center perspective. *Cancer Med*. 2020;9(17):e141-146.
 32. Lorusso D, Ray-Coquard I, Oaknin A, Banerjee S. Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? *ESMO Open*. 2020;5(5):e000924.
 33. McDermott MM, Newman AB. Preserving clinical trial integrity during the coronavirus pandemic. *J Am Med Assoc*. 2020;323(21):2135-2136.
 34. Cagnazzo C, Besse M-G, Manfellotto D, et al. Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future? *Tumori J*. 2021;107(1):6-11.
 35. Sekeres M. Contract Research Agonizations. ASH Clinical News. 2017. Available at <https://www.ashclinicalnews.org/viewpoints/editors-corner/contract-research-agonizations/>. Accessed August 2, 2021.
 36. Waterhouse DM, Harvey RD, Hurley P, et al. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology survey. *JCO Oncol Pract*. 2020;16(7):417-421.
 37. Izmailova ES, Ellis R, Benko C. Remote monitoring in clinical trials during the COVID-19 pandemic. *Clin Transl Sci*. 2020;13(5):838-841.
 38. Li G, Yin C, Zhou Y, et al. Digitalized adaptation of oncology trials during and after COVID-19. *Cancer Cell*. 2020;38(2):148-149.
 39. Nabhan C, Choueiri TK, Mato AR. Rethinking clinical trials reform during the COVID-19 pandemic. *JAMA Oncol*. 2020;6(9):1327-1329.
 40. Shimizu H, Nakayama KI. Artificial intelligence in oncology. *Cancer Sci*. 2020;111(5):1452-1460.
 41. Van Booven DJ, Kuchakulla M, Pai R, et al. A systematic review of artificial intelligence in prostate cancer. *Res Rep Urol*. 2021;13:31-39.
 42. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. *Cancer Discov*. 2021;11(4):900.
 43. Bleiberg H, Decoster G, de Gramont A, et al. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. *Ann Oncol*. 2017;28(5):922-930.
 44. Grady C. Enduring and emerging challenges of informed consent. *N Engl J Med*. 2015;372(9):855-862.
 45. Chen C, Lee P-I, Pain KJ, Delgado D, Cole CL, Campion TR. Replacing paper informed consent with electronic informed consent for research in academic medical centers: a scoping review. *AMIA Summits Transl Sci Proc*. 2020;2020:80-88.
 46. Abel J. Compassionate communities and end-of-life care. *Clin Med Lond Engl*. 2018;18(1):6-8.
 47. Perrenoud B, Velonaki V-S, Bodenmann P, Ramelet A-S. The effectiveness of health literacy interventions on the informed consent process of health care users: a systematic review protocol. *JBI Evid Synth*. 2015;13(10):82-94.
 48. Kendir C, Breton E. Health literacy: from a property of individuals to one of communities. *Int J Environ Res Public Health*. 2020;17(5):1601.
 49. European Commission. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. Report No.: ENTR/F/2/SF/jr (2009)D/869. Available at https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/2009_01_12_readability_guide_line_final_en.pdf. Accessed August 2, 2021.

50. Mathibe LJ. Drop-out rates of cancer patients participating in longitudinal RCTs. *Contemp Clin Trials*. 2007;28(4):340-342.
51. Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. *J Natl Cancer Inst*. 2019;111(3):245-255.
52. Skea ZC, Newlands R, Gillies K. Exploring non-retention in clinical trials: a meta-ethnographic synthesis of studies reporting participant reasons for drop out. *BMJ Open*. 2019;9(6):e021959.
53. Sathian B, Asim M, Banerjee I, et al. Impact of COVID-19 on clinical trials and clinical research: a systematic review. *Nepal J Epidemiol*. 2020;10(3):878-887.
54. Haffner I, Schierle K, Raimúndez E, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. *J Clin Oncol*. 2021;39:1468-1478.
55. Wosik J, Fudim M, Cameron B, et al. Telehealth transformation: COVID-19 and the rise of virtual care. *J Am Med Inform Assoc*. 2020;27(6):957-962.
56. Padala PR, Jendro AM, Padala KP. Conducting clinical research during the COVID-19 pandemic: investigator and participant perspectives. *JMIR Public Health Surveill*. 2020;6(2):e18887.
57. Doshi A, Platt Y, Dressen JR, Matthews BK, Siy JC. Keep calm and log on: telemedicine for COVID-19 pandemic response. *J Hosp Med*. 2020;15(5):301-304.
58. NZ Telehealth forum and resource center. Guideline for Establishing and Maintaining Sustainable Telemedicine Services in New Zealand. Available at <https://www.telehealth.org.nz/regulations-and-policies/regulations-and-standards/>. Accessed August 2, 2021.
59. Bakker JP, Goldsack JC, Clarke M, et al. A systematic review of feasibility studies promoting the use of mobile technologies in clinical research. *NPJ Digit Med*. 2019;2:47.
60. Mooney K, Berry DL, Whisenant M, Sjoberg D. Improving cancer care through the patient experience: how to use patient-reported outcomes in clinical practice. *Am Soc Clin Oncol Educ Book*. 2017;37:695-704.
61. Cox SM, Lane A, Volchenboum SL. Use of wearable, mobile, and sensor technology in cancer clinical trials. *JCO Clin Cancer Inform*. 2018;2:1-11.
62. Cagan R, Meyer P. Rethinking cancer: current challenges and opportunities in cancer research. *Dis Model Mech*. 2017;10(4):349-352.
63. Lyman GH, Kuderer NM. Randomized controlled trials versus real-world data in the COVID-19 era: a false narrative. *Cancer Invest*. 2020;38(10):537-542.
64. The global challenge of cancer. *Nat Cancer*. 2020;1(1):1-2.
65. Kim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. *J Clin Oncol*. 2017;35(33):3737-3744.
66. van Marum RJ. Underrepresentation of the elderly in clinical trials, time for action. *Br J Clin Pharmacol*. 2020;86(10):2014-2016.
67. US Food and Drug Administration (FDA). Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections. Silver Spring, MD: FDA; 2020. Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus>. Accessed August 2, 2021.
68. Lin NU, Prowell T, Tan AR, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology—Friends of Cancer Research Brain Metastases Working Group. *J Clin Oncol*. 2017;35(33):3760-3773.
69. Magnuson A, Bruinooge SS, Singh H, et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. *Clin Cancer Res*. 2021;27(9):2424-2429.
70. Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? *BMC Med*. 2017;15(1):134.
71. Del Paggio JC, Berry JS, Hopman WM, et al. Evolution of the randomized clinical trial in the era of precision oncology. *JAMA Oncol*. 2021;7(5):728-734.
72. Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. *JAMA Oncol*. 2017;3(3):382-390.
73. US Food and Drug Administration (FDA). FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval. Silver Spring, MD: FDA; 2021. Available at <https://www.fda.gov/news-events/fda-brief/fda-brief-fda-oncologic-drugs-advisory-committee-review-status-six-indications-granted-accelerated>. Accessed August 2, 2021.
74. Doshi P. Will covid-19 vaccines save lives? Current trials aren't designed to tell us. *BMJ*. 2020;371:m4037.
75. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384(15):1412-1423.
76. Pawlowski C, Lenahan P, Puranik A, et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. *medRxiv*. 2021;2021. <https://doi.org/10.1101/2021.02.15.21251623>.
77. Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. *BMJ*. 2021;372:n149.
78. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. *BMJ*. 2021;372:n699.
79. US Food and Drug Administration (FDA). *Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review*. Silver Spring, MD: FDA; 2019. Available at <https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review>. Accessed August 2, 2021.
80. European Medicines Agency (EMA). Conditional Marketing Authorisation. Amsterdam, The Netherlands: EMA; 2018. Available at <https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation>. Accessed August 2, 2021.
81. European Medicines Agency (EMA). PRIME: Priority Medicines. Amsterdam, The Netherlands: EMA; 2018. Available at <https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines>. Accessed August 2, 2021.